Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) saw a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 4,025,930 shares, a decrease of 16.7% from the January 15th total of 4,830,166 shares. Based on an average daily trading volume, of 751,145 shares, the short-interest ratio is currently 5.4 days. Approximately 5.7% of the shares of the stock are short sold. Approximately 5.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 751,145 shares, the short-interest ratio is currently 5.4 days.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters bought 6,459,973 shares of the stock in a transaction dated Wednesday, December 31st. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the transaction, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. The trade was a 91.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Vincent Vultaggio sold 29,951 shares of the firm’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the completion of the transaction, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,546,617 shares of company stock worth $10,088,417 in the last quarter. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Tybourne Capital Management HK Ltd. grew its holdings in shares of Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after purchasing an additional 516,666 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Zentalis Pharmaceuticals by 4.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock valued at $3,241,000 after buying an additional 124,985 shares in the last quarter. Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at about $59,000. Y Intercept Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals in the 2nd quarter worth about $38,000. Finally, SG Americas Securities LLC grew its stake in Zentalis Pharmaceuticals by 35.3% in the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after acquiring an additional 8,236 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ZNTL shares. Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Morgan Stanley reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average target price of $5.00.

Zentalis Pharmaceuticals Trading Up 2.1%

ZNTL stock opened at $2.39 on Monday. The stock has a market cap of $172.68 million, a PE ratio of -1.15 and a beta of 1.72. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.95. The company has a 50-day moving average price of $2.18 and a 200 day moving average price of $1.75.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.